logo_300 × 140.png

SPONSORSHIP PROSPECTUS

24 - 26 August 2023 | the Westin, Perth

Terms & Conditions

The following are part of the contract between the partner and the congress managers, MCI Australia, and exhibitors/partners must observe these rules. In addition, any regulations imposed by the venue must also be observed. Any areas not covered are subject to MCI’s final decision.

  • The following terms and conditions apply to your participation as a sponsor.
  • You (the sponsor) by returning a completed, signed and dated form explicitly accept these terms and conditions.
  • Details may change without notice. Please refer to the congress website for the latest information.
  • MCI Australia (ABN 76 108 781 988) representing the organising committee and the Host body does not accept responsibility for any errors, omissions or changes.
  • You agree that the organisers and other authorised stakeholders may use your contact information for any relevant purpose such as administration or advising of future events. You may ask us to limit communication to necessary matters.
  • The Platform and MCI do not take responsibility should internet connection become unstable. Internet connection is out of the control of MCI Australia and the Platform provider, it is the responsibility of the delegate/sponsor/stakeholder to have stable connection to access the platform.
  • We will use reasonable endeavours to provide constant, uninterrupted access to the Platform and the Services, but with any software product, this cannot be guaranteed. We will not be responsible or liable for any direct or indirect losses or damages suffered or sustained by you as a result of, or in connection with, any interruption or delay in accessing and using the Platform or the Services Use of the platform
  • Modify the platform or merge any aspects of the platform with another programme other than as expressly provided under this Agreement.
  • Record, reverse engineer, copy, duplicate, reproduce, create derivate works from, frame, download, display, transmit or distribute any of the Platform, the source code of the Platform or any documents, manuals or setup instructions provided with the Platform or in relation to the Services
  • License, sell, rent, lease, transfer, assign or otherwise commercially exploit the Platform or the Services
  • Engage in unlawful behaviour, including unauthorised access to or use of data, services, systems or networks, including an attempt to probe, scan or test the vulnerability of a system or network or to break security or authentication measures
  • Access, store, distribute or transmit:
    • Viruses, work, trojan or other malicious code that corrupts, degrades or disrupts the operation of the Platform;
    • Material that is unlawful, unethical, harmful, threatening, defamatory, obscene, infringing, harassing or racially or
    • ethnically offensive or a contravention of the rights of any third party;
    • Material that facilitates illegal activity, or
    • Material that abuses or causes damage or injury to any person or property
    • Provide Platform login details or password, or otherwise provide access to the Platform, to any unauthorised or unregistered third party and you will take all reasonable steps to prevent unauthorised access to, or use of, the Platform;
  • Share any features of the Platform that are not publicly available with any unauthorised third part; and
  • Engage in any conduct on the Platform that is in breach of this Agreement (or any agreements mentioned therein)
  • Any breach of this clause 1 constitutes a breach of this Agreement and we may, at our absolute discretion, terminate or suspend your access to, and/or use of, the Platform or the Services, and/or take further actions against you for breach of this Agreement.
  • All Services will be provided based on the information and specifications supplied by you. All information that we provide is supplied in good faith, but we do not warrant or guarantee the accuracy or completeness of any information provided by us or any third party. It is not within the scope of our obligations to enquire as to, or to verify, the accuracy of completeness of information that we receive from your or any third parties.
  • The Services, Deliverables and any Platform functionality specified in previous conversations are indicative only and may be amended by us from time to time. While we will use all reasonable endeavours to deliver the features and functionality specified therein, nothing in this Agreement prevents us from amending the Services at any time during the event delivery.
  • We will use reasonable endeavours to provide the Services promptly or by an applicable Delivery Date or such other dates as agreed by the parties in writing. Any Delivery Date or time quoted for delivery, commencement or completion of any part of the Services is an estimate only and time will not be of the essence.
  • You acknowledge that our ability to be able to provide the Services to you without delate or interruption is dependent on your full and timely cooperation. You will (and will ensure that the Authorised Users will):
    • Co-operate with and assist us in the supply of your content;
    • Promptly provide us with full and accurate information, data and explanations as and when required;
    • Comply with applicable laws and regulations (including the General Data Protection regulation (“GDPR”) with respect to user privacy, data collection, data retention, data transmission, data storage and the use of cookies
    • Comply with all reasonable directions and guidelines from us as advised from time to time.
  • We will have no liability for any losses suffered or any damage caused by errors or omissions in any information or instructions provided to us by you in connection with the Platform, the Services or any actions taken by as at your direction.
  • Phone or unpaid bookings will not be accepted
  • We will issue a tax invoice which is payable within 14 days. If you miss the payment date, any time dependent discounts will be forfeited— i.e. you will be billed at the next highest level (early rate to standard, etc.
  • You will not receive any sponsorship entitlements, until all monies have been paid.
  • All sponsorship prices in this prospectus are in AUD ex GST (10%)
  • If you pay by credit card a payment processing fee may be applied
  • If you pay by electronic funds transfer you agree to pay any bank charges and must include these in the amount you transfer
  • In no event will MCI Australia/ANZCHOG be liable to you or any third party for any:
    • Loss of profits, revenue, goodwill or business, business interruption, corruption, loss or alteration of data, downtime costs, loss of use, failure to realise anticipated savings or for any indirect or consequential loss of damage of whatsoever nature, however caused;
    • Viruses worm, trojan or other malicious code introduced into, or transmitted to, your or any third part during the course of using the Platform or the Services;
  • Your application to sponsor does not constitute an attendee registration. You will need to do that separately as per the
  • information provided in the technical manual.
  • You must notify us in writing if you need to cancel
  • Cancellations made on or before Tuesday 28 Feb 2023 will be refunded less 50% cancellation fee.
  • Your non-payment does not cancel your contractual obligations to us
  • In the unlikely case that the event cancels, ANZCHOG will refund your full financial investment minus any expenses incurred to date of the cancellation. This includes, but not limited to, platform costs for your program involvement and any promotional exposure up until the time cancellation occurs.
  • In the unlikely case that the event postpones or changes format significantly from what is outlined in this prospectus the extent of refunds will be a matter for the Host Organisation (the underwriter) to decide. The ANZCHOG 2023 ASM will forward requests for annulment of contract or refund to MCI Australia for arbitration.

 

  • Your application to sponsor does not constitute an attendee registration. You will need to do that separately as per the information provided in the technical manual.
  • Your staff (even if entitled to a complimentary registration) will be denied access to the event unless they have completed the relevant registration form.

Echo Therapeutics is an Australian Pharmaceutical and Medical Technology Company, specialising in products and services for the Hospital sector in Australia and New Zealand. Our aim is to gain deep customer insights to resolve unmet needs.

Partnering with global and local groups, we will build complementary suites of products and services for the ANZ markets that will have a meaningful impact on our customers and patients lives.

Our goal is to work with ANZCHOG to improve access to medicines in paediatric oncology.

Servier is a privately owned pharmaceutical company, governed by a non-profit foundation that is committed to therapeutic progress to serve patient needs. Servier has a long-standing commitment to research and development.

Worldwide approximately 25% of branded product turnover is reinvested into research and development through the Servier Foundation, with half of that investment dedicated to research to help fight cancer.
Servier has significant investment in new products in early development in the areas of Oncology and Haematology with broad research and development platforms in cancer cell apoptosis and immuno-oncology. Servier Australia is also home to the Asia-Pacific clinical trial hub.
Servier is proud to support innovative partnering programs with world class institutions including WEHI in Australia to further advance scientific understanding in the area of oncology. For further information see the website www.servier.com.au

Servier Australia’s oncology products include Oncaspar (pegaspargase), Lonsurf® (trifluridine/tipiracil) and Onivyde® (nanoliposomal irinotecan as sucrosofate).

A/Prof Yasmin Jayasinghe

The Royal Children’s Hospital Melbourne

AProf Yasmin Jayasinghe (FRANZCOG, PhD) is a paediatric gynaecologist , Director of the Oncofertility Program at The Royal Children’s Hospital Melbourne and the Australian representative on the Practice Committee of the global Oncofertility Consortium.  She is founding Chair of the Australian New Zealand Consortium in Paediatric Oncofertility (ANZCO), and is Principal Investigator of the binational ANZCO clinical trials network driven by ANZCHOG champions, who were recently awarded  a $3million MRFF for ‘Life Saving and Job Creating Medical Research’. She was founding chair of the Fertility Preservation Taskforce in Victoria in 2012, who in partnership with consumers pioneered Australia’s first ethically governed paediatric oncofertility program, oncofertility registry (scaled up to the Future Fertility Registry by A Anazodo), and oncofertility nurse navigators. The taskforce have been recognized as finalists in: the Vic Health Awards for facilitating equitable access to oncofertility care; the Australian Nurse of the Year awards for nurse navigation; and three statewide Young Achiever Awards for oncofertility innovation. AProf Jayasinghe has received many honours and in 2021 was a national finalist for the Australian Human Rights Medal for pioneering the protection of the reproductive rights of children.

Dr Justin Baker

St Jude Children’s Research Hospital

Dr Baker is the Division Chief of Quality of Life and Palliative Care at St. Jude Children’s Research Hospital, Memphis, TN, USA. He is trained in paediatric haematology/oncology, as well as Hospice and Palliative Medicine. Dr Baker is a world leader in paediatric palliative care and quality of life, with over 100 publications in the field. His research focuses on integrating palliative care into the ongoing care of children with cancer, the ethical consideration of early phase trials, and paediatric palliative care in developing countries. He was awarded the AAHPM Inspirational Leader in Hospice and Palliative Medicine in 2014, and the St. Jude Communicator of the Year in 2017. Dr Baker has led the development of guidelines in paediatric palliative care and quality of life that have been implemented in centres throughout the world, and has been an invited speaker at paediatric oncology and palliative care conferences across the globe.

Proudly supported by

Dr Robert Battisti

Children’s Hospital Westmead

DR ROB BATTISTI | CLINICAL PSYCHOLOGIST | BPSYCH (HONS), PhD (CLINICAL PSYCHOLOGY) | FACPA | LEUT RAN

Rob Battisti is a Senior Clinical Psychologist and head of Psycho-oncology at the Cancer Centre for Children at the Children’s Hospital at Westmead and a Clinical Director at Mind Plasticity, a large multi-disciplinary mental health practice in Sydney. He is passionate about delivering evidence-based therapies and overcoming some of the traditional barriers that restrict people from accessing top quality care via team care arrangements. A key focus of his work is mental health service development, including policy, governance and clinical training. His goal in children’s cancer services is to ensure that mental wellness, education and future quality of life are placed firmly in the treatment mix.

Rob completed his PhD at the University of Wollongong and a postdoctoral position with the National Drug and Alcohol Research Centre (NDARC) at the University of New South Wales in partnership with the Brain and Mind Centre (BMC) at the University of Sydney. He has worked in and around Sydney for many years and has professional affiliations with organisations such as the BMC, headspace and St Vincent’s Private Hospital. He has additionally served on the Board of Directors for the Australian Clinical Psychology Association (ACPA) of which he is a Fellow member.

Rob has expertise in working with individuals and families with more complex needs and in multi-disciplinary care arrangements. His clinical background is in child, adolescent and young adult (AYA) psychology as well as parenting psychology, with expertise in cancer and other areas of health psychology, addiction, and psychiatric comorbidity (i.e. multiple diagnoses).

Rob also consults to organisations on preventative mental health and is a Lieutenant Psychologist with the Royal Australian Navy.

Prof Paul Monagle

University of Melbourne

Professor Monagle is an internationally renowned paediatric haematologist and haemato-pathologist. He is a Professor of Paediatrics at the University of Melbourne, a clinical Haematologist at the Kids Cancer Centre, Sydney Children’s Hospital, and an Honorary Fellow and Group Leader in Haematology Research at the Murdoch Children’s Research Institute. Professor Monagle is a world expert on thrombosis and coagulation, with over 300 publications in the field of paediatric haematology. His research group holds multiple NHMRC grants and is currently leading work into COVID-19 associated thrombosis. Professor Monagle was awarded the Outstanding Research Award in Paediatric Cardiology by the American Heart Association in 2008, and delivered the Barry Firkin Oration for the Thrombosis & Haemostasis Society of Australia and New Zealand in 2018. He has played a key role in designing multiple international multi-centre trials, and been an invited speaker at haematology conferences across the globe.

Prof Marcus Vowels

Professor Vowels is a renowned early leader of the paediatric oncology and haematology disciplines in Australia. Professor Vowels established the first bone marrow transplant program in Australia at the then Prince of Wales Children’s Hospital, now Sydney Children’s Hospital in Randwick, NSW. Professor Vowels established the Australian Cord Blood Bank and was a founding trustee of the Australian Cord Blood Foundation. Professor Vowels has over 100 peer reviewed publications, he was the founding member of a number of editorial boards of discipline specific journals and is the author of multiple book chapters. Professor Vowels was the President of the Australian and New Zealand Children’s Cancer Study Group from 1990 to 1994, and was awarded a Member of the Order of Australia (AM) for his service to medicine, particularly in the fields of childhood leukaemia and cancer.

Annabel Crabb

ABC Journalist

Annabel Crabb is one of Australia’s most beloved journalists. She is an ABC writer and presenter who has covered Australian politics for 20 years but also is nationally well-known for her insightful and humorous analysis on gender and current affairs. 

Annabel recently created and presented the ground breaking Ms Represented, unearthing stories from the 100 years of women in Australian parliaments. For the ABC, she has also devised and presented six seasons of the enormously popular Kitchen Cabinet, and “The House with Annabel Crabb – the fly-on-the-wall documentary on Australian Parliament.” She also presents the ABC’s hit culinary history series Back In Time For Dinner, and co-stars in Tomorrow Tonight with Charlie Pickering.

With friend and ABC colleague Leigh Sales, Australia’s pre-eminent current affairs journalist, Annabel hosts the top-rating podcast Chat 10 Looks 3. Their first book together, Well Hello, was published in September 2021.

Annabel is an avid baker and proud mother of three.

Dr Robert Battisti

Children’s Hospital Westmead

Dr Battisti is a Clinical Psychologist and Researcher at the Cancer Centre for Children at the Children’s Hospital at Westmead, and an Honorary Research Associate at the University of Sydney. Dr Battisti completed his PhD at the University of Wollongong and a postdoctoral position with the National Drug and Alcohol Research Centre (NDARC) at the University of New South Wales in partnership with the Brain and Mind Centre at the University of Sydney. Dr Battisti is also on the Board of Directors for the Australian Clinical Psychology Association (ACPA). His clinical background is in child, adolescent and young adult (AYA) psychology as well as parenting psychology, with expertise in paediatric cancer including childhood cancer survivorship.

Bayer is a global life science company with expertise in healthcare and agriculture. The company has had a presence in Australia since 1925 and has a long-term commitment to the health and nutrition of all Australians and New Zealanders. As people live longer and the population continues to grow both locally and beyond, Bayer is one of the few companies that takes a comprehensive view of these issues. Guided by our purpose – Science for a better life – we apply our global scientific expertise in healthcare and agriculture to deliver innovations locally to help people and the planet thrive.

Bayer employs almost 900 people across Australia and New Zealand and is dedicated to servicing the needs of rural and remote communities. Bayer embraces and encourages its employees’ unique identities and advances a culture of inclusion and diversity across gender, LGBTQIA+, generations, disability and race.

For further information visit www.bayer.com.au

MISSION: WE CHANGE LIVES, PATIENT BY PATIENT

At EUSA we are committed to transforming the lives of people affected by cancer or rare disease, globally.

We continuously strive to uncover opportunities which address gaps across adult and paediatric care – through development opportunities, acquiring, and in-licensing therapies.

Helping the people with few or no options available is at the heart of everything we do at EUSA. Every day, we are proud to make a difference – building a company around our people, our values, and our mission.

We see a need. We work together. We don’t give up.

Breakthroughs That Change Patients’ Lives: Pfizer is a leading research-based biopharmaceutical company. We apply science and our global resources to deliver innovative therapies that extend and significantly improve lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Vencare Medical

ECP made EASY! Flexible two-step ECP that works for you! info@vencaremedical.com.au

The Robert Connor Dawes (RCD) Foundation was created in June 2013 in the memory of Robert ‘Connor Dawes’ who lost his 16-month battle with an ependymoma brain tumour at just 18 years of age. The RCD Foundation works to support brain matters projects in the areas of research, care and development – to fund the science to fight paediatric brain cancer and support patients in the meantime.

The Foundation operates in Australia and the US, and to date has invested $3.45M into paediatric brain cancer research, funding basic science and translational projects, as well as capacity building grants through fellowships, scholarships and travel grants. It has also leveraged another $10M, leading collaborative research initiatives. In addition to funding and partnering with Australian research institutes and Foundations, RCD is also active member of the Child’s Brain Tumour Network (CBTN), Paediatric Neuro-Oncology Consortium (PNOC) and the Collaborative Ependymoma Research Network (CERN). We leverage our research investments through partnering with like-minded and passionate organisations to continue to battle paediatric brain cancer.

Our history
The Kids’ Cancer Project is an independent national charity supporting childhood cancer research. Since 1993, the charity has contributed more than $50 million dollars to scientific research projects to help children with many different types of cancer.

Our Goal
Mission: To support bold scientific research that has the greatest chance of clinical success in the improvement of treatments of childhood cancers.

Vision: One hundred per cent survival for children with cancer while eradicating the harmful impacts treatment can bring.

What we stand for
Science: We believe the only way to improve outcomes for kids with cancer is through advances in medical research.

Solutions: Our research priorities reflect our focus on finding better treatments, building research capabilities and supporting survivorship programs.

Survival: Our founder, Col Reynolds OAM, made a promise
to never give up until a cure is found.

BD is one of the largest global medical technology companies in the world and is advancing the world of healthTM by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare.

eviQ and eviQ Education are programs of the Cancer Institute NSW, a state government cancer control agency. Both programs have a national target audience and an international reach.

eviQ provides free online evidence-based, consensus driven cancer treatment protocols and information for use at the point of care. eviQ is developed for the Australian context and supports health professionals in the delivery of cancer treatments.

eviQ Education provides free, evidence-based cancer eLearning resources for health professionals.

For more than 20 years, Illumina has aspired to improve human health by unlocking the power of the genome. As we move towards precision medicinein pediatric cancer, we have only just begun to discover the true impact of genomics. Learn how Illumina technologies is enabling novel insights into childhood cancer risk and treatment. Visit: https://sapac.illumina.com/destination/Precision-Medicine-in-Pediatric-Cancers.html

Jazz Pharmaceuticals is a global Biopharmaceutical Company whose purpose is to transform the lives of patients and their families through innovation. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options so they can live their lives more fully.

We have a diverse portfolio of marketed medicines and novel product candidates, from early- to latestage development, in Neuroscience and Haematology/Oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science.

Jazz Pharmaceuticals has employees around the globe including Australia and New Zealand, serving patients in nearly 75 countries

Medical Information
Phone: 1800577422
Email: medinfo-apac@jazzpharma.com

Adverse event
Phone: 1800577422
Email: AEReporting@jazzpharma.com


To report a Product Complaint, please email:
productcomplaints@jazzpharma.com

A/Prof Jordan Hansford

Women’s and Children’s Hospital Adelaide

Jordan is a mid-career clinician specializing in the treatment of paediatric brain tumours. He has a long-standing interest in cancer genetics post the completion of his Master’s of Science in Cancer Genetics at Queen’s University, Canada. Upon the completion of his clinical training and admission to fellowship, he relocated to Melbourne where he led the team’s neuro-oncology and clinical research teams. Most recently he has relocated to Adelaide where he is developing a Neuro-Oncology research program at SAHMRI/SAiGENCI and the new Bragg Proton Radiotherapy Centre. He is currently the chair of the ANZCHOG brain group.

Proudly supported by

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Novartis has more than 60 years’ history in Australia and employ around 600 associates across its two divisions.

At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases.

Through bold and transformative science, we’re driving innovation that has the potential to become the next generation of life-changing medicines. Our ambition is evident in our mission. Because the impossible is not impossible. It’s what’s next.

Leukaemia & Blood Cancer New Zealand (LBC) is New Zealand’s national charity dedicated to supporting patients, and their families/whānau, living with a blood cancer or a serious blood condition.

Join the ANZCHOG ASM mailing list

Stay informed with the latest updates
* indicates required